Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, immunogenicity, and viral shedding of MEDI-534, a live, attenuated intranasal vaccine against respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3), in healthy RSV and PIV3 seropositive 1-9 year-old children

Trial Profile

A phase I, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, immunogenicity, and viral shedding of MEDI-534, a live, attenuated intranasal vaccine against respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3), in healthy RSV and PIV3 seropositive 1-9 year-old children

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MEDI 534 (Primary)
  • Indications Parainfluenza virus infections; Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jul 2009 Results published in The Pediatric Infectious Disease Journal.
    • 02 May 2008 Results presented at PAS 2008.
    • 30 Jul 2007 Status changed from in progress to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top